In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Poseida withdraws IPO filing, goes for $142mm Series C round instead

Executive Summary

Poseida Therapeutics Inc. (CART treatments for cancer and gene therapies for orphan genetic diseases) raised $142mm through a Series C round. Novartis Pharma AG led with a $75mm investment, and was joined by new investors Aisling Capital Management, Pentwater Capital Management, Perceptive Advisors, and other undisclosed institutional investors, along with returning backers Malin Corp. PLC, Longitude Capital, Vivo Capital, and Boxer Capital (Tavistock). The Series C was announced concurrent with Poseida withdrawing its filing for an initial public offering. The company filed for the IPO in January, but after a series of delays and expressed interest from investors, opted to cancel the IPO and take in the Series C funds instead.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies